Nextbiotix has raised €7 million ($8 million) to develop a bacterial treatment for inflammatory bowel diseases. The series A round will support work to rebalance the gut microbiome through the delivery of Faecalibacterium prausnitzii, one of the most abundant species of bacteria in the gut.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,